Biotech
Endeavor BioMedicines
Endeavor BioMedicines raises $132.5M Series C at $650M valuation
$132.5M
Total Raised
Series C
Latest Round
2019
Founded
80+
Employees
San Diego, CA
1 min read
Quick Facts
Valuation
$650M
Latest Round Size
$132.5M
Latest Round Date
April 2024
Endeavor BioMedicines: Series C Funding Round
Endeavor BioMedicines has successfully raised $132.5M in Series C funding, reaching a valuation of $650M.
Company Overview
Developing medicines for idiopathic pulmonary fibrosis
Funding Details
The Series C round was led by AyurMaya, with participation from Polaris Partners.
Company Information
- Headquarters: San Diego, CA
- Founded: 2019
- Employees: 80+
- Category: Biotech
Investment
Endeavor BioMedicines plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- AyurMaya: Verified investor in Series C
- Polaris Partners: Verified investor in Series C
Key Investors
AyurMaya
Lead Investor
Verified investor in Series C
Polaris Partners
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Editorial Team
Oct 8, 2025
1 min read•$153M